21st Century Cardio-Oncology
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy an...
Main Authors: | Calvin Chen Sheng, MD, Laleh Amiri-Kordestani, MD, Todd Palmby, PhD, Thomas Force, MD, Charles C. Hong, MD, PhD, Joseph C. Wu, MD, PhD, Kevin Croce, MD, PhD, Geoffrey Kim, MD, Javid Moslehi, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-08-01
|
Series: | JACC: Basic to Translational Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X16300559 |
Similar Items
-
The Establishment of the Nordic Cardio-Oncology Society
by: Agneta Månsson Broberg, MD, PhD, et al.
Published: (2020-06-01) -
Working Together to Advance Cardio-Oncology in China
by: Yunlong Xia, MD, PhD, et al.
Published: (2020-03-01) -
Evolving field of cardio-oncology
by: Guo Li, et al.
Published: (2023-04-01) -
Cardio-Oncology in Iran: Cardio-toxicity Registry
by: Azin Alizadehasl, et al.
Published: (2022-08-01) -
Cardio-oncology: need for novel structures
by: Lars Michel, et al.
Published: (2019-01-01)